Studies of Populations Exposed to Therapeutic Medical Radiation and Other Agents

暴露于治疗性医学辐射和其他药物的人群的研究

• 批准号: 9154184
• 负责人: Amy Berrington
• 金额: $ 305.28万
• 依托单位: DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9154184
• 关键词: Accounting; Age; Alkylating Agents; Benign; Bone Marrow Transplantation; Brachytherapy; Breast; Breast Cancer survivor; Cancer Survivor; Cells; Cervix Uteri; Childhood Cancer Survivor Study; Chronic; Contralateral; Data; Databases; Diagnosis; Disease; Disease model; Dose; Esophagus; Etiology; Evaluation; External Beam Radiation Therapy; Feasibility Studies; Genes; Genetic; Gynecologic; Heart Diseases; Hematologic Neoplasms; Hematopoietic Neoplasms; Hodgkin Disease; Incidence; Individual; Intensity-Modulated Radiotherapy; International; Ionizing radiation; Japanese Population; Late Effects; Life Style; Localized Malignant Neoplasm; Malignant Childhood Neoplasm; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Malignant neoplasm of esophagus; Malignant neoplasm of pancreas; Malignant neoplasm of testis; Malignant neoplasm of thyroid; Medical; Medicare; Methods; Modeling; Monitor; Monograph; Multiple Myeloma; Mutation; Neoplasms; Nested Case-Control Study; Non-Hodgkin' s Lymphoma; Outcome; Pancreas; Patients; Peptic Ulcer; Pharmaceutical Preparations; Population Study; Protons; Publications; Publishing; RB1 gene; Radiation; Radiation Interaction; Radiation therapy; Research Personnel; Resources; Retinoblastoma; Risk; Risk Factors; SEER Program; Salivary Glands; Second Primary Cancers; Skin; Solid Neoplasm; Statistical Models; Stomach; Survivors; Therapeutic; Thyroid Gland; Tissues; Uncertainty; Update; Woman; Work; bone; cancer risk; cancer therapy; chemotherapy; childhood cancer survivor; cohort; dosimetry; follow-up; gastrointestinal; genome wide association study; interest; internal radiation; leukemia; malignant breast neoplasm; malignant stomach neoplasm; mathematical model; melanoma; mortality; neoplasm registry; novel; response; soft tissue; tumor

REB investigators evaluate the risks of multiple cancers following all cancers using the Surveillance Epidemiology and End Results Program cancer registry database including more than 2 million cancer survivors diagnosed from 1973 to 2008. Interesting findings from the 2006 Multiple Primary Monograph have been followed up with individual studies evaluating risk of radiation-related and chemotherapy-related second cancers. Particular studies of interest include of survivors of breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, retinoblastoma, and childhood cancers. In 2012 the first estimates of the proportion of second cancers related to radiotherapy were published.Cancer Following Radiotherapy for Benign Gynecologic Disorders - Cancer mortality following radiation treatment for benign gynecologic conditions in a cohort of nearly 15,000 women with individual radiation dose data is being updated to evaluate solid tumor and leukemia risk. Results were submitted for publication in 2012.Childhood Cancer Survivor Study - In a cohort of 14,000 5-year survivors of childhood cancer we performed nested case-control studies of second primary cancers of the breast, thyroid gland, salivary gland, bone, soft tissue and skin to evaluate the relationship between radiation and chemotherapy and risk of these cancers. A novel finding was that thyroid cancer risk was related to prior treatment with alkylating agents among patients exposed to radiation less than 20 Gy to the thyroid. New analyses of second breast cancers in relation to prior cancer treatment and potential effect modifiers has been initiated. The CCSS also is a unique resource and a rare opportunity in which to examine the potential for gene-radiation interaction. Particularly noteworthy are the availability of biospecimens, high quality information on doses of radiation and chemotherapy, and the young age at exposure of the cohort. We are currently performing a genome wide association study of subsequent neoplasms within this cohort (10597).Cancer Risk in Peptic Ulcer Patients - A of cohort of 2000 irradiated peptic ulcer patients is being compared to 2000 non-irradiated peptic ulcer patients to refine the dose-related risk for all cancers and cardiac disease and model the uncertainty in the dose estimates for these outcomes.Proton and intensity-modulated radiation therapy have the potential to deliver maximal doses to the tumor while minimizing dose to the surrounding tissues which may cause second cancers. Feasibility work in SEER-Medicare and local cancer registries is in progress.RF Analysis of Hematopoietic Malignancies in Various Radiotherapeutically Irradiated Cohorts - Parallel analysis using a variety of mathematical and statistical models of cancer risks associated with ionizing radiation exposure in the Japanese atomic bomb survivors and in therapeutically irradiated groups. Endpoints include all hematologic cancers, specifically leukemia (including chronic lymphocytc leukemia (CLL)), Hodgkins disease, non-Hodgkins lymphoma (NHL), and multiple myeloma. The models take account of cell repopulation and redistribution as a result of internal and external radiation exposure (including brachytherapy), and also factors such as age at exposure and attained age.Radiation Dose-Response and Second Primary Cancers of Stomach, Esophagus, and Pancreas - An international study of second primary gastrointestinal (GI stomach cancer, pancreatic cancer, and esophageal cancer) cancers is being conducted among survivors of Hodgkin lymphoma testis cancer, breast and cervical cancer to provide new data on radiation dose and subsequent risk of GI cancer. Findings to date have demonstrated a dose-related increased risk of esophageal cancer following breast cancer. Analyses of GI malignancy risk after HL and testis and cervical cancers as well as related dosimetry methods projects are in progress.Risk Factors for Second Cancers in the Cohort Consortium - The feasibility of studying second cancers in the NCI Cohort Consortium is being assessed.Second Cancers after Breast Cancer in Kaiser - The etiology of contralateral breast is probably related to treatment, genetic and lifestyle risk factors. We are exploring the feasibility of studying treatment and modifiable lifestyle risk factors for contralateral breast cancer in three different cohorts. Second Cancers Following Retinoblastoma - A cohort of 1,850 Retinoblastoma survivors continues to be monitored for the incidence and mortality of all second primary cancers, primarily of the bone, soft tissue, and melanoma in relation to past radiotherapy and chemotherapy. Studies of RB1 mutations and second cancer risks are in progress.

REB研究人员使用监视流行病学和最终结果癌症注册表数据库评估了多种癌症的风险，其中包括1973年至2008年诊断出的200万次癌症幸存者。2006年的多个主要专着的有趣发现，对评估了与放射相关和化学治疗疗法相关的二级二级癌症的个人研究进行了跟进。 感兴趣的特定研究包括乳腺癌幸存者，霍奇金淋巴瘤，非霍奇金淋巴瘤，视网膜母细胞瘤和儿童期癌症。 2012年，发布了与放射疗法相关的第二癌比例的第一个估计值。放射治疗后用于良性的妇科疾病后 - 在近15,000名具有近15,000名具有个人放射剂量数据的女性的良性妇科疾病的良性妇科治疗后的癌症死亡率正在更新中，以评估固体肿瘤和leukemia风险。 结果于2012年提交出版。儿童癌症幸存者研究 - 在14,000个儿童癌症的14,000名5年幸存者中，我们对乳腺癌的第二个主要癌症进行了嵌套的病例对照研究，甲状腺，甲状腺，唾液腺，唾液腺，骨骼，软组织和皮肤，以评估放射疗法和化学疗法和风险之间的关系。一个新的发现是，甲状腺癌的风险与暴露于甲状腺小于20 Gy的患者中的烷基化剂先前治疗有关。已经开始了第二种乳腺癌与先前的癌症治疗和潜在效应修饰剂有关的新分析。 CCSS也是一种独特的资源，也是一个难得的机会，可以在其中检查基因辐射相互作用的潜力。特别值得注意的是生物测量的可用性，有关放射剂量和化学疗法的高质量信息以及队列暴露时的年轻年龄。我们目前正在对该队列中随后的肿瘤进行一项基因组广泛的关联研究（10597）。在消化性溃疡患者中癌风险 - 2000个辐照消化性溃疡患者的同伴与2000名非摩擦式消化性溃疡患者进行了比较，以使所有剂量估计的剂量估计的风险和刺激性的疾病量的降级，并在这些剂量上估计。结果。普罗顿和强度调节的放射疗法具有将最大剂量输送到肿瘤的潜力，同时最大程度地减少可能导致第二次癌症的周围组织的剂量。 RF在各种放射治疗辐射的同类群中对造血性恶性肿瘤进行了进展。终点包括所有血液癌，特别是白血病（包括慢性淋巴细胞性白血病（CLL）），霍奇金斯疾病，非霍奇金斯淋巴瘤（NHL）和多发性骨髓瘤。 The models take account of cell repopulation and redistribution as a result of internal and external radiation exposure (including brachytherapy), and also factors such as age at exposure and attained age.Radiation Dose-Response and Second Primary Cancers of Stomach, Esophagus, and Pancreas - An international study of second primary gastrointestinal (GI stomach cancer, pancreatic cancer, and esophageal cancer) cancers is being conducted among霍奇金淋巴瘤睾丸癌，乳腺癌和宫颈癌的幸存者提供有关辐射剂量以及随后发生胃肠道癌风险的新数据。迄今为止的发现表明，乳腺癌后剂量相关的食管癌风险增加。 HL，睾丸和宫颈癌以及相关的剂量方法项目的分析正在进行中。生活方式风险因素。我们正在探索研究治疗和可修改的生活方式危险因素的可行性，以在三种不同的同伴中对侧乳腺癌。视网膜细胞瘤之后的第二癌 - 1,850个视网膜母细胞瘤幸存者的队列继续受到监测的所有第二次主要癌症的发病率和死亡率，主要是骨骼，软组织和黑色素瘤与过去的放射疗法和化学疗法有关。 RB1突变和第二种癌症风险的研究正在进行中。